ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.53
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,195.86
0.65%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cingulate Inc (CINGW)

  7. Cingulate Inc (CINGW) News

Cingulate (CINGW)

Cingulate Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CINGW
DateTimeSourceHeadlineSymbolCompany
08/05/202412:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CINGWCingulate Inc
08/05/202412:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
08/05/202412:00GlobeNewswire Inc.Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
30/04/202410:45GlobeNewswire Inc.Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessNASDAQ:CINGWCingulate Inc
16/04/202422:00GlobeNewswire Inc.Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024NASDAQ:CINGWCingulate Inc
01/04/202413:00GlobeNewswire Inc.Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
19/03/202420:45GlobeNewswire Inc.Cingulate to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
06/03/202411:45GlobeNewswire Inc.Cingulate to Attend DCAT Week 2024 in New York CityNASDAQ:CINGWCingulate Inc
13/02/202411:45GlobeNewswire Inc.Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsNASDAQ:CINGWCingulate Inc
06/02/202421:15GlobeNewswire Inc.Cingulate Announces Closing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
02/02/202414:15GlobeNewswire Inc.Cingulate Announces Pricing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
29/01/202413:00GlobeNewswire Inc.Longtime Cingulate Controller Jennifer Callahan Promoted to CFONASDAQ:CINGWCingulate Inc
29/01/202411:45GlobeNewswire Inc.Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketNASDAQ:CINGWCingulate Inc
01/12/202314:00GlobeNewswire Inc.Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)NASDAQ:CINGWCingulate Inc
13/11/202321:15GlobeNewswire Inc.Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
17/10/202319:22GlobeNewswire Inc.Cingulate to Host CNS Key Opinion Leader Panel in New York CityNASDAQ:CINGWCingulate Inc
21/09/202318:30GlobeNewswire Inc.Cingulate Inc. to Present at the LD Micro Main Event XVINASDAQ:CINGWCingulate Inc
13/09/202321:15GlobeNewswire Inc.Cingulate Announces Closing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
11/09/202314:22GlobeNewswire Inc.Cingulate Announces Pricing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
11/09/202311:00GlobeNewswire Inc.Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
08/09/202321:31GlobeNewswire Inc.Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a PremiumNASDAQ:CINGWCingulate Inc
05/09/202313:00GlobeNewswire Inc.Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023NASDAQ:CINGWCingulate Inc
14/08/202321:15GlobeNewswire Inc.Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
11/07/202313:00GlobeNewswire Inc.Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
29/06/202313:00GlobeNewswire Inc.Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and AugustNASDAQ:CINGWCingulate Inc
14/06/202320:45GlobeNewswire Inc.Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-VestNASDAQ:CINGWCingulate Inc
08/06/202312:00GlobeNewswire Inc.Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
25/05/202320:55GlobeNewswire Inc.Cingulate to Present at 13th Annual LD Micro InvitationalNASDAQ:CINGWCingulate Inc
12/05/202320:45GlobeNewswire Inc.Cingulate, Indegene to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
10/05/202321:15GlobeNewswire Inc.Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
 Showing the most relevant articles for your search:NASDAQ:CINGW

Your Recent History

LATK
WAGMIGAMESUSDT
WAGMI GAMES
LSE
V3GU
Vanesggcua
USOTC
LTNC
Labor Smart (PK)
TSX
REAX
Real Brokerage
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved